Genitourinary Radiation Oncologist, Holman-trained @ Moffitt. Student of bladder and penile cancer. Trying to be a physician-scientist. Tweets=own
Tampa, FL
Joined September 2017
- Tweets222
- Following572
- Followers352
- Likes1.1K
G. Daniel Grass MD, PhD retweeted
BOND-003 Cohort C data in @TheLancetOncol
A 75% CR rate at any time, with a median follow-up of 25.8 months and no grade 3/4 treatment-related adverse events, represents an important contribution to the evolving treatment landscape for BCG-unresponsive NMIBC.
Advances like this don’t happen overnight. They are built on patients willing to participate, investigators who believe early, committed clinical teams, and industry partners who stay the course.
Science is a team sport. Congratulations to everyone involved.
sciencedirect.com/science/ar…
@MarkTysonMD @UrogerliMD @garysteinbergmd @tbivala1 @JamesBurke34034 @cgoncology @KuanArthur @IBCG_BladderCA
G. Daniel Grass MD, PhD retweeted
Love the candid discussion that this tweet has generated! Posted prior to flight, now back after #FIFA26 and #Wimbledon (congrats @janniksin) , so let me post some of my thoughts on this 🧵
If a patient in front of you refuses RC after EVP, the honest answer is enrollment in a prospective surveillance protocol with predefined imaging and biopsy triggers for salvage therapy. (EV-209; NCT07475806)
NOT quiet endorsement of surveillance as standard of care.
@scserendipity1 @tompowles1 @AndreaNecchi @shilpaonc @siadaneshmand @UrogerliMD @bbmdmsk @joanfundi @IBCG_BladderCA @drenriquegrande @JoshMeeks
G. Daniel Grass MD, PhD retweeted
pCR at cystectomy have reached levels not seen before after neoadjuvant therapy and are increasingly being proposed as a surrogate endpoint for clinical trials, but ... does improving pCR reliably predict improving overall survival?
In our collaborative study in @EurUrolOncol we analyzed 12 prospective neoadjuvant trials (3,119 patients) using a formal two-step trial-level surrogacy framework. @Pietro9609 @AndreaNecchi @drenriquegrande @BenjaminPradere @DrShariat @AlisonBirtle @OncoBellmunt @MRoupret
@ThoSeisen @laconss @slusarczyk_alek @UroMoschini
🧵
G. Daniel Grass MD, PhD retweeted
🤩 Finally OUT in @JCO_ASCO!
BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy
A decade of persistence from @VedangMurthy ☺️
@RadOncTMC @TataMemorial @ACTREC_TMC
@PaulSargos
@Xristodouleas
ascopubs.org/doi/full/10.120…
G. Daniel Grass MD, PhD retweeted
Priority Editorial!
When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era by Martino Pedrani et al
Read the full article: buff.ly/n6uKXj0
We thank the authors for their insight.
@PedraniMartino
@DeGiorgiAlberto
@AndreaGallina5
@UrsulaVogl
@ZilliThomas
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
G. Daniel Grass MD, PhD retweeted
In which patients is metastases-directed therapy without systemic therapy sufficient? Presentation by @KOSJ12 @MoffittNews. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4umwR3E @APCCC_Lugano
G. Daniel Grass MD, PhD retweeted
New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)
Full text: authors.elsevier.com/a/1mf5C…
@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
G. Daniel Grass MD, PhD retweeted
Congrats @JJCaudell @BeekeepRadOnc @DrKedarKirtane @CHChungMD on this novel phase II trial personalizing radiation dose for HPV+ oropharyngeal cancer using PSI @MoffittNews @MoffittRadOnc
Our phase II trial to personalize RT fractionation for very low risk HPV+ oropharyngeal cancer patients using PSI (a pre-treatment model of growth dynamics).
authors.elsevier.com/a/1mYur…
G. Daniel Grass MD, PhD retweeted
We’ve treated polymetastatic disease as “too much” for RT for decades.
Our new review in @IJROBP dives into the practical realities of treating widespread disease with SABR + immunomodulatory LDRT - from patient selection to workflows that scale. @MoffittNews @drdavidpalma
Practical Aspects of Delivering Radiation for Poly-metastatic Disease
authors.elsevier.com/c/1mYQo…
@celloradonc
G. Daniel Grass MD, PhD retweeted
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer | FDA@ great news for our patients @MayoClinic @shilpaonc @PGrivasMDPhD fda.gov/drugs/resources-info…
G. Daniel Grass MD, PhD retweeted
From #ASTRO25: Kosj Yamoah, MD (@KOSJ12), shared findings on the Decipher genomic classifier and Artera multimodal AI biomarker in predicting metastasis in localized prostate cancer. Both outperform traditional risk tools.
Key findings:
➡️ In 306 prostate cancer cases, Decipher and Artera scores showed only weak overall correlation.
➡️Each was independently linked to distinct biological pathways in metastatic patients.
➡️Together, they may offer complementary value in defining aggressive disease.
learn more: amportal.astro.org/sessions/…
#MoffittASTRO25
Awesome work @NakashimaJustyn! One of our chiefs @MoffittRadOnc soon to provide excellent care to many patients in the Orlando area 💪🏻
From #ASTRO25 : Justyn Nakashima, DO (@NakashimaJustyn) shares institutional outcomes of SBRT for extracranial oligometastatic renal cell carcinoma during the poster Q&A.
Results indicate that SBRT is safe and effective, delaying systemic therapy while maintaining high LC and PFS.
#MoffittASTRO25
G. Daniel Grass MD, PhD retweeted
At the #ASTRO25 plenary session, Vedang Murthy, MD, (@VedangMurthy @TataMemorial) shares clinical outcomes of adjuvant radiotherapy (RT) after radical cystectomy (RC) and chemotherapy in locally advanced muscle-invasive bladder cancer (LA-MIBC).
➡️ Adjuvant RT improved LRFS and DFS without increased severe late toxicity in patients with LA-MIBC post cystectomy and chemotherapy.
➡️ Potential benefit in OS is being explored in a planned individual patient data meta-analysis of randomized trials.
Read more: amportal.astro.org/sessions/…
#MoffittASTRO25 @ASTRO_org
Strong 💪🏻 work from a stellar resident @celinachiodo presenting @MoffittNews early experience with online hypofx adaptive bladder radiation. Awesome support by @MoffittRadOnc physics in making this an option for our patients
G. Daniel Grass MD, PhD retweeted
Incredibly honored to be 1 of 12 residents in the country to receive a Recognition Meeting Abstract Award for our work on Adaptive Radiotherapy for Locally Advanced Lung Cancer. So thankful for my mentors and Moffitt Cancer Center for supporting our research. #ASTRO25
Great job @DK_18621 presenting your research on the use of ctDNA in post-TMT surveillance. Much to learn with this data. 🚨 Rising ⭐️ @MoffittRadOnc @MoffittNews
G. Daniel Grass MD, PhD retweeted
HOT OFF THE PRESS! Neoadjuvant PAE prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation - ctro.science/article/S2405-6…
@MoffittNews @MoffittRadOnc @KOSJ12 @gdgrass @VaseemKhatri @ctRO_journal
G. Daniel Grass MD, PhD retweeted
I often hear that post-TMT cystectomy is “fraught with complications even in experienced hands.”
That hasn’t been my experience.
With the right principles and disciplined technique, these cases can be remarkably straightforward. Maybe I’m delusional - but curious to hear what others think. What’s been your experience?
@siadaneshmand @drgaganprakash @joanfundi @bbmdmsk @UrogerliMD @MarekBabjuk @MariaJRibal @AlisonBirtle @ParamMariappan @LauraBukavinaMD @SimaPorten @nnavai @MaxKates @SpiessPhilippe @paolo_gontero @VedangMurthy #OncSurgery @MRoupret @garysteinbergmd
G. Daniel Grass MD, PhD retweeted
Radiation vs systemic therapy for isolated pelvic recurrence after cystectomy. @UroDocAsh moderates a debate between @AndreaNecchi @SanRaffaeleMI & Comron Hassanzadeh, MD, MPH @MDAndersonNews. Comron Hassanzadeh backs pelvic radiation for isolated recurrence, while Andrea Necchi highlights systemic therapy with EV-pembro and data from EV-302 & CheckMate-901. Both stress the importance of biomarkers, patient input & multidisciplinary care.
🎥 #WatchNow > bit.ly/3TdQBpF
